Tag
KT-253, a selective MDM2 protein degrader, shows potent elimination of malignant myelofibrosis stem/progenitor cells by enhancing p53 pathway activation, outperforming current MDM2 inhibitors and offering a promising therapeutic advance.
This review elucidates fibrocytes’ critical role in JAK2V617F-mutated myelofibrosis pathogenesis and evaluates pitavastatin’s promising therapeutic effects in reversing marrow fibrosis and anemia, integrating mechanistic insights and
Loss of FAP-1 disrupts megakaryocyte membrane development and platelet function through aberrant Src activation, leading to myelofibrosis-like pathology with potential therapeutic targeting by Src inhibition.
The combination therapy of azacitidine and ruxolitinib demonstrates a 72% overall response rate in myelofibrosis patients, highlighting enhanced efficacy beyond JAK2 inhibitor monotherapy in a phase II clinical trial.
This study evaluates non-invasive biomarkers to differentiate essential thrombocythemia, premyelofibrosis, and overt myelofibrosis, revealing distinct inflammatory and immune profiles and supporting a disease continuum model.
